Jaundice is a critical global health issue among newborns

Jaundice is the #1 reason why newborns are readmitted to hospitals worldwide. About 3 in 5 children have some degree of jaundice. For approximately 18% of babies, the condition is severe and requires treatment. Severe jaundice, when left untreated or ineffectively treated, can lead to severe brain damage, a condition called kernicterus, or death.

Millions of babies are not receiving the effective care they need

With experts at Stanford University School of Medicine, we estimate that every year, over 6 million babies with severe jaundice are not receiving adequate treatment.1

1 “BK Cline, R Vilms, K. McGraw, HH Lou, KM Donaldson, VK Bhutani. Global Burden and Unmet Need for Hyperbilirubinemia Treatment. Poster session presented at: Pediatric Academic Society; 2011 April 30-May 3; Denver, CO.”

Every year, over
6 million babies
with severe jaundice are not receiving adequate treatment

Yet, jaundice is easy to treat.
If detected early enough, it simply
requires shining intense blue light
onto a baby’s skin

Current treatment devices are costly to purchase and maintain

In studies of medical facilities in India and Nigeria, D-Rev and Stanford found that 95% of devices evaluated in low-income hospitals and clinics did not meet American Academy of Pediatrics standards for intensive phototherapy.2,3 Maintenance was a key limitation in delivery of treatment: approximately 1 in 3 phototherapy devices had at least one bulb burned out or missing. Compact florescent bulbs, commonly used in phototherapy devices, cost approximately $15 per bulb to replace and last approximately four months. Many hospitals have trouble sourcing these bulbs and, with devices using an average of six bulbs each, they simply can’t afford to replace them as needed.

2 Cline, Benjamin K., et al. “Phototherapy device effectiveness in Nigeria: irradiance assessment and potential for improvement.” *Journal of tropical pediatrics* (2013): fmt027.
3 Cline BK, Daly RE, Donaldson KM, et al: Evaluation of Phototherapy Device Efficacy in Resource-Limited Nurseries. Pediatric Academic Societies. Abstract 1496:535, 2010. Available at:http://www.abstracts2view.com/pas/view. Accessed March 17, 2011

95%

Of devices in low-income hospitals and clinics did not meet American Academy of Pediatrics standards

1 in 3 devices had at least one bulb burnt out or missing

We are starting where the need is most critical

We learned from our fieldwork and due diligence that urban and district hospitals rarely have effective phototherapy—in fact only 5% in our target areas. To reach the most newborns, Brilliance is designed for hospitals where the sickest children are treated. district sized hospitals with NICUs who treat the sickest children.

The Design

World-Class Technology

• Peak wavelength 450–465nm
• Uniform intensity >45µW/cm²/nm
• Effective treatment area >1300cm²

SmartTilt Technology

Patent-pending technology to ensure that light intensity from blue LEDs is consistent across the treatment footprint at any angle of head-tilt. SmartTiltTM ensures that Brilliance Pro works effectively at any position with other newborn care equipment.
Brilliance Pro only

Energy Efficient

Brilliance consumes less than half the electricity of CFLs.

Integrated Design

Brilliance is designed for versatility of use. Brilliance can be integrated with other critical medical equipment such as infant warmers, incubators, and nearly any variety of bassinet.

Minimal Maintenance

Brilliance LEDs last 60x longer than compact fluorescent lamps (CFL) commonly used in phototherapy devices. With Brilliance, hospitals can save over $240 USD per year on costly bulb replacements. Also, Brilliance can withstand a wide range of power fluctuations without changes in device performance.

Made in India, designed in USA

Compare Brilliance Models

Brilliance Pro

plus light meter
Brilliance Pro

D-Rev’s most groundbreaking product to-date. With sophisticated programming and advanced design, Brilliance Pro has an integrated light meter, expanded functionality, and a sleek look to work better in the NICU.

Brilliance Classic

Brilliance Classic

The original design of Brilliance Classic combines world-class performance with the most affordable price for a phototherapy unit to treat severe jaundice in the most resource-limited hospitals.

Brilliance Underside

Brilliance Underside

Designed with Phoenix Medical Systems in India, Brilliance Underside works in tandem with both Classic and Pro when double-sided phototherapy is needed to accelerate treatment.

Integrated Light Meter (available)

true

true

true

LED Lifetime

120,000 hours

120,000 hours

120,000 hours

LED Intensity

>45µW/cm²/nmat recommended treatment distance of 35cm

>45µW/cm²/nmat recommended treatment distance of 35cm

>30µW/cm²/nmat fixed treatment distance

High & Low Settings

true

true

true

Peak Wave-length of Light

450-465nm

450-465nm

450-465nm

SmartTilt Technology

true

true

true

Tilting LED Panel

0–90°

0–90°

Tilts with bassinet

Adjustable Height

true

true

Fixed height

Therapy Timer

true

true

true

Total Machine Run Timer

true

true

true

CE Mark

Pending

CE 0843

CE 0843

Product Launch Date

January 2015

November 2012

March 2013

Base Retail Price w/ 1-year warranty

$400 USD

$400 USD

$400 USD

Backlit LCD Screen

true

true

true

Observation Lights (available)

true

true

true

Passive Cooling (no fan)

true

true

true

D-Rev research and collaborations

The Need to Implement Effective Phototherapy in Resource-Constrained Settings

Device Effectiveness in Nigeria: Current Irradiance Levels and Simple Strategies for Improvement

A Global Strategy to Screen and Prevent the Need for the Exchange Transfusion

The Delivery

In late 2010, D-Rev licensed Brilliance Classic to Phoenix Medical Systems in Chennai, India. Phoenix is the largest manufacturer and seller of quality neonatal care equipment in India with 70% of the market share of compact florescent bulb phototherapy devices in the country. Brilliance Classic was released on the market in November 2012. Phoenix is currently manufacturing, distributing, and selling Brilliance throughout India and much of the rest of the world.

About The Deal

About The Deal
Phoenix

The licensing agreement is structured to incentivize sales to public hospitals in India and low-income countries. Specifically, the target markets are countries categorized by the United Nations Human Development Index as low or medium resource-limited. Through dialogue with Indian medical professionals, D-Rev and Phoenix have agreed to cap the selling price of Brilliance units based on the cost of goods sold to ensure affordability in emerging and undercapitalized markets.
• Brilliance Classic – $400 USD
• Brilliance Pro – $400 USD
• Brilliance Underside – $400 USD

About Phoenix

Established in 1989, Phoenix is committed to quality, technology, and innovation with an excellent in-house research and development team. Phoenix products are trusted worldwide and used in almost all premier hospital and medical institutions in India. Phoenix has ISO certifications and pursues international standards in ensuring the highest safety of all its products.

Brilliance is on the market and can be ordered directly through our partner, Phoenix Medical Systems

Order Brilliance

Order Brilliance

The Impact

Impact 175,700

babies treated with Brilliance

Impact 148,000

babies treated who would not otherwise have received effective treatment

Impact 2,300

newborn deaths and disabilities averted

Impact 1,730

units installed

View Full Dashboard